AU2020394597B2 - 1,2,4-oxadiazole derivatives as liver X receptor agonists - Google Patents

1,2,4-oxadiazole derivatives as liver X receptor agonists Download PDF

Info

Publication number
AU2020394597B2
AU2020394597B2 AU2020394597A AU2020394597A AU2020394597B2 AU 2020394597 B2 AU2020394597 B2 AU 2020394597B2 AU 2020394597 A AU2020394597 A AU 2020394597A AU 2020394597 A AU2020394597 A AU 2020394597A AU 2020394597 B2 AU2020394597 B2 AU 2020394597B2
Authority
AU
Australia
Prior art keywords
phenyl
methyl
oxadiazol
trifluoromethyl
phenoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
AU2020394597A
Other languages
English (en)
Other versions
AU2020394597A1 (en
Inventor
Kelly D. BOSS
Yi Fan
Alec Nathanson FLYER
Declan HARDY
Zhihong Huang
Kathryn Taylor Linkens
Jon Christopher LOREN
Fupeng Ma
Valentina Molteni
Duncan Shaw
Jeffrey Smith
Catherine Fooks Solovay
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2020394597A1 publication Critical patent/AU2020394597A1/en
Application granted granted Critical
Publication of AU2020394597B2 publication Critical patent/AU2020394597B2/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2020394597A 2019-11-25 2020-11-23 1,2,4-oxadiazole derivatives as liver X receptor agonists Expired - Fee Related AU2020394597B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962940061P 2019-11-25 2019-11-25
US62/940,061 2019-11-25
US202063106293P 2020-10-27 2020-10-27
US63/106,293 2020-10-27
PCT/IB2020/061053 WO2021105857A1 (en) 2019-11-25 2020-11-23 1,2,4-oxadiazole derivatives as liver x receptor agonists

Publications (2)

Publication Number Publication Date
AU2020394597A1 AU2020394597A1 (en) 2022-06-02
AU2020394597B2 true AU2020394597B2 (en) 2024-03-14

Family

ID=73654860

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020394597A Expired - Fee Related AU2020394597B2 (en) 2019-11-25 2020-11-23 1,2,4-oxadiazole derivatives as liver X receptor agonists

Country Status (22)

Country Link
US (2) US11427586B2 (https=)
EP (1) EP4065228A1 (https=)
JP (1) JP2023503320A (https=)
KR (1) KR20220106778A (https=)
CN (1) CN114746149A (https=)
AU (1) AU2020394597B2 (https=)
BR (1) BR112022009942A2 (https=)
CA (1) CA3157657A1 (https=)
CL (1) CL2022001323A1 (https=)
CO (1) CO2022006645A2 (https=)
CR (1) CR20220227A (https=)
DO (1) DOP2022000107A (https=)
EC (1) ECSP22040362A (https=)
IL (1) IL291958A (https=)
JO (1) JOP20220124A1 (https=)
MX (1) MX2022006151A (https=)
PE (1) PE20221785A1 (https=)
PH (1) PH12022551248A1 (https=)
PY (1) PY2077235A (https=)
TW (1) TW202132289A (https=)
UY (1) UY38964A (https=)
WO (1) WO2021105857A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024518128A (ja) * 2021-05-20 2024-04-24 ノバルティス アーゲー ３－（（３－（４－（２－（イソブチルスルホニル）フェノキシ）－３－（トリフルオロメチル）フェニル）－１，２，４－オキサジアゾール－５－イル）メチル）－５，５－ジメチル－１－（２－モルホリノエチル）イミダゾリジン－２，４－ジオンの製剤
WO2022249006A1 (en) * 2021-05-24 2022-12-01 Novartis Ag Use of 1,2,4-oxadiazole derivatives as liver x receptor agonists
KR102882404B1 (ko) 2022-10-28 2025-11-06 (주)케이메디켐 신규 옥사디아졸 유도체, 이의 제조방법 및 이를 포함하는 인지기능 개선용 조성물

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015187840A2 (en) * 2014-06-03 2015-12-10 Duke University Methods and formulations for treatment of ocular disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201120016A (en) 2009-12-08 2011-06-16 Abbott Lab Novel oxadiazole compounds
US8729109B2 (en) * 2011-09-08 2014-05-20 Allergan, Inc. 3-(4-(5-phenyl-1 ,2,4-oxadiazol-3-yl)phenoxy)propan-2-ol derivatives as sphingosine-1phosphate receptors modulators
WO2013131018A1 (en) 2012-03-02 2013-09-06 Zalicus Pharmaceuticals Ltd. Biaryl inhibitors of the sodium channel
JP2022514257A (ja) 2018-12-13 2022-02-10 アイノス，インコーポレイテッド ドライアイ疾患の治療のための局所点眼製剤におけるｌｘｒアゴニスト

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015187840A2 (en) * 2014-06-03 2015-12-10 Duke University Methods and formulations for treatment of ocular disorders

Also Published As

Publication number Publication date
MX2022006151A (es) 2022-08-02
EP4065228A1 (en) 2022-10-05
US11427586B2 (en) 2022-08-30
JOP20220124A1 (ar) 2022-05-23
TW202132289A (zh) 2021-09-01
ECSP22040362A (es) 2022-06-30
PY2077235A (es) 2022-10-31
CO2022006645A2 (es) 2022-05-31
PH12022551248A1 (en) 2023-09-11
US20220340573A1 (en) 2022-10-27
UY38964A (es) 2021-06-30
CN114746149A (zh) 2022-07-12
IL291958A (en) 2022-06-01
JP2023503320A (ja) 2023-01-27
DOP2022000107A (es) 2022-06-15
AU2020394597A1 (en) 2022-06-02
CL2022001323A1 (es) 2023-03-24
CA3157657A1 (en) 2021-06-03
PE20221785A1 (es) 2022-11-22
WO2021105857A1 (en) 2021-06-03
BR112022009942A2 (pt) 2022-08-09
KR20220106778A (ko) 2022-07-29
CR20220227A (es) 2022-06-15
US20220064164A1 (en) 2022-03-03

Similar Documents

Publication Publication Date Title
WO2021047622A1 (zh) 吡啶氮氧化合物及其制备方法和用途
US20220340573A1 (en) 1,2,4-oxadiazole derivatives as liver x receptor agonists
US20240043403A1 (en) Heteroaryl carboxamide compound
JP2007536369A (ja) プロリン及びモルホリン誘導体の新規化合物
US12435040B2 (en) 1,3-substituted cyclobutyl derivatives and uses thereof
JP2019532077A (ja) 治療用化合物及びその使用方法
AU2024275602A1 (en) Sulfonamide compound, preparation method therefor, and pharmaceutical use thereof
WO2024148308A1 (en) Novel, reversible dpp1 inhibitors and uses thereof
RU2730520C2 (ru) Твердые формы альфа, омега дизамещенного дигидроксициклопентильного соединения и способы их получения и применения
US20230002366A1 (en) Indene derivatives useful in treating pain and inflammation
CA2995161A1 (en) 2,3,4,5-tetrahydropyridin-6-amine derivatives
EP4702026A1 (en) Tricyclic fused imidazole compounds as cd38 modulators and uses thereof
RU2640047C2 (ru) Соль производного пирролидин-3-ил-уксусной кислоты и ее кристаллы
WO2018149991A1 (fr) Dérivés sulfonamides hydroxylés en tant qu'agonistes inverses du récepteur gamma orphelin associé aux rétinoïdes ror gamma (t)
CN119118894A (zh) Trpv4受体配体
WO2022249006A1 (en) Use of 1,2,4-oxadiazole derivatives as liver x receptor agonists
BR122025005591A2 (pt) Uso de e processo para preparação de derivados de ciclobutila 1,3-substituída, combinação farmacêutica, e kit
BR122025005591B1 (pt) Uso de e processo para preparação de derivados de ciclobutila 1,3- substituída, combinação farmacêutica, e kit
BR112023019496B1 (pt) Derivados de ciclobutila 1,3-substituída, e composição farmacêutica
JP2009517483A (ja) 一酸化窒素シンターゼの二量化の抑制剤としてのイミダゾール誘導体
EA050893B1 (ru) Производные 1,3-замещенного циклобутила и способы их применения
JP2025531367A (ja) Ｔｒｐｖ１アンタゴニストの結晶多形形態およびその製剤

Legal Events

Date Code Title Description
MK25 Application lapsed reg. 22.2i(2) - failure to pay acceptance fee